 AstraZeneca PLC LSE:AZN said a drug it has developed jointly with Merck has been approved for use in women with advanced ovarian cancer by the Chinese authorities. Lynparza has been signed off as a maintenance treatment for a sub-group of women that have the HRD-positive form of the disease. 